The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Pharmacogenetics in Psychopharmacology: Personalized Medication Selection and Dosing

Genetic testing of drug metabolism enzymes and pharmacodynamic targets to guide psychiatric medication choice and dosing

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Psikiyatri department. Book Appointment →

What is Pharmacogenetics in Psychopharmacology: Personalized Medication Selection and Dosing?

Pharmacogenetics studies genetic variation effects on drug response examining metabolism, transport and target receptor polymorphisms.

CYP2D6 metabolizes many antidepressants and antipsychotics with poor metabolizers experiencing higher levels and ultrarapid lower levels at standard doses.

CYP2C19 metabolizes citalopram, escitalopram, sertraline and other antidepressants with phenotype affecting clinical exposure.

HLA-B*1502 testing predicts severe carbamazepine-induced Stevens-Johnson syndrome particularly in Asian populations and is required pre-treatment.

Pharmacogenetic test panels combine multiple gene assessments providing actionable recommendations for medication selection.

Symptoms

Treatment-resistant depression with multiple medication trial failures may benefit from pharmacogenetic testing identifying metabolizer status.
Adverse drug reactions out of proportion to dose may indicate poor metabolizer phenotype with elevated drug levels.
Lack of efficacy at standard doses may suggest ultrarapid metabolism with subtherapeutic levels despite adequate prescribing.
Drug interactions may be pharmacogenetically modulated with phenoconversion converting genotypic intermediate to functional poor metabolizer.
Polypharmacy with substrates and inhibitors of same metabolic pathway requires consideration of pharmacogenetic effects on combinations.

Risk Factors

Treatment failure across multiple medication trials suggesting poor metabolic activity or pharmacodynamic non-response patterns.
Severe adverse reactions including serotonin syndrome, prolonged sedation or cardiac events at therapeutic doses suggest metabolic considerations.
Family history of medication intolerance or treatment failure may suggest hereditary pharmacogenetic patterns worth investigating.
Specific ethnic backgrounds with higher prevalence of metabolic variants including East Asian for CYP2C19 and HLA-B*1502.
Polypharmacy combining multiple psychotropics or interacting medications increases relevance of pharmacogenetic information.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Two or more failed adequate medication trials in major depressive disorder may suggest pharmacogenetic testing benefit.
  • Severe adverse drug reactions to standard doses warrant consideration of metabolic explanation through pharmacogenetic testing.
  • Treatment of patients with relevant ethnic backgrounds for specific medications including carbamazepine prescription consideration.
  • Specialist consultation including psychiatric pharmacology or pharmacogenomics expertise guides interpretation and clinical application.
  • Clinical pharmacogenetics implementation consortium guidelines provide standardized recommendations available through online resources.

Treatment Methods

01
Targeted pharmacogenetic testing including CYP2D6, CYP2C19 and other relevant genes guides medication selection and dosing.
02
Test interpretation with phenotype assignment to poor, intermediate, normal, rapid or ultrarapid metabolizer guides prescribing decisions.
03
Medication selection avoiding substrates of poor metabolizer pathways or selecting alternatives with different metabolic routes.
04
Dose adjustments based on phenotype with reduced doses for poor metabolizers or higher doses or alternatives for ultrarapid metabolizers.
05
Integration with clinical decision support, medication management programs and patient education promotes effective implementation while traditional clinical factors including efficacy assessment, drug interactions and patient preferences remain primary considerations.

Which Department to Visit?

You can visit our Psikiyatri department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Psikiyatri Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Generalized Anxiety Disorder (GAD)

Psikiyatri

Generalized anxiety disorder is characterized by excessive, difficult-to-control worry most days for at least six months, accompanied by physical symptoms such as muscle tension, fatigue, and sleep disturbance that impair daily functioning.

Psychiatric Insomnia and Sleep Disorders

Psikiyatri

Effects of depression, anxiety and other psychiatric disorders on sleep and their treatment.

Depression

Psikiyatri

What is depression, how does it differ from sadness, and how is it treated?

Anxiety Disorder

Psikiyatri

What is anxiety disorder, how does it differ from normal worry, and how is it overcome?

Panic Attack

Psikiyatri

What is a panic attack, how is this condition — often confused with a heart attack — managed and prevented?

OCD (Obsessive Compulsive Disorder)

Psikiyatri

What is OCD, how are intrusive thoughts and compulsive behaviors treated?

PTSD (Post-Traumatic Stress Disorder)

Psikiyatri

What is PTSD, how are flashbacks and hyperarousal after trauma treated?

Bipolar Disorder

Psikiyatri

Bipolar disorder is a chronic mood disorder characterized by episodes of mania or hypomania alternating with depressive episodes; accurate diagnosis and long-term treatment with mood stabilizers are essential to reduce relapses and improve functioning.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.